Company: BDRX
Filing Date: 2025-05-23
Form Type: 6-K
Source: 0001214659-25-008302
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-23
Form: 6-K
Chunk 1
---
 information in this Form 6-K and the exhibits attached thereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of May 2025 is:

| Exhibit No. 
 99.1        |     | Description                                                                  
 Annual Report for the year ended December 31, 2024                           |
|:------------|:----|:-----------------------------------------------------------------------------|
| 99.2        |     | Notice of Annual General Meeting                                             |
| 99.3        |     | Annual General Meeting Form of Proxy (Holders of Ordinary Shares)            |
| 99.4        |     | Annual General Meeting Form of Proxy (Holders of American Depositary Shares) |

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: May 23, 2025 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:-------------------|:----------------------------|:----------------------------------------------------|
|                    |                             | Stephen Stamp                                       |
|                    |                             | Chief Executive Officer and Chief Financial Officer |